Enliven Therapeutics (ELVN) Non Operating Income (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Non Operating Income data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 31.29% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.0 million (up 9.42% YoY), and the FY2025 full-year result was $16.0 million, up 3.11% from the prior year.
• Non Operating Income slipped to $4.2 million in Q1 2026, from $4.6 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.9 million in Q3 2025 to a low of $9000.0 in Q1 2022.
• A 5-year average of $2.9 million and a median of $3.3 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income plunged 89.16% in 2022 and soared 18722.22% in 2023, its largest moves.
• Tracing ELVN's Non Operating Income over 5 years: stood at $613000.0 in 2022, then surged by 445.84% to $3.3 million in 2023, then soared by 30.16% to $4.4 million in 2024, then rose by 6.04% to $4.6 million in 2025, then decreased by 9.14% to $4.2 million in 2026.
• Business Quant data shows ELVN's Non Operating Income at $4.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.9 million in Q3 2025.